Radiopharmaceuticals and theranostics: reshaping cancer diagnosis and therapy with targeted radionuclides
RSC Advances · 2026 · 16 (49) · 65938-65959
DOI: 10.1039/d6ra06959b ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift RSC Advances, 2026. Verfasst von Humaira Zulfiqar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, COMSATS University Islamabad Abbottabad 22044 Pakistan humairazulfiqar774@gmail.com. Die Arbeit nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
This review traces radiopharmaceutical theranostics from radiobiological mechanism to pivotal trials, highlighting alpha-emitting radionuclides and AI-guided dosimetry as the field's next frontier.
Autor:innen und Institutionen
- Department of Chemistry, COMSATS University Islamabad Abbottabad 22044 Pakistan humairazulfiqar774@gmail.com.
- Department of Math and Natural Sciences, Gulf University for Science and Technology Hawally 32093 Kuwait.
ORCID-Profile: Humaira Zulfiqar, Muhammad Waqas, Ijaz Ali
Zitieren
APA
Zulfiqar, H., Waqas, M., & Ali, I. (2026). Radiopharmaceuticals and theranostics: reshaping cancer diagnosis and therapy with targeted radionuclides. RSC Advances, 16(49), 65938-65959. https://doi.org/10.1039/d6ra06959b
Vancouver
Zulfiqar H, Waqas M, Ali I. Radiopharmaceuticals and theranostics: reshaping cancer diagnosis and therapy with targeted radionuclides. RSC Advances. 2026;16(49):65938-65959. doi:10.1039/d6ra06959b
BibTeX
@article{Zulfiqar2026,
author = {Zulfiqar, Humaira and Waqas, Muhammad and Ali, Ijaz},
title = {Radiopharmaceuticals and theranostics: reshaping cancer diagnosis and therapy with targeted radionuclides},
journal = {RSC Advances},
year = {2026},
volume = {16},
number = {49},
pages = {65938--65959},
doi = {10.1039/d6ra06959b}
}
EUVIMED